AI-guided ultrasound and MRI staging to guide bladder cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will build a multimodal dataset linking contrast-enhanced ultrasound, magnetic resonance images, pathology slides, clinical data, and follow-up for patients with suspected bladder cancer. They will preprocess and homogenize imaging, perform tissue segmentation with U-Net and Transformer-based methods, and train convolutional neural networks with attention mechanisms and transfer learning to derive staging and prognostic models. Tumor specimens will undergo immunohistochemical fluorescence staining to add molecular information and support multimodal feature extraction. The project is observational and will enroll surgical candidates at a single center to test the models' ability to stage disease and stratify risk.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ultrasound and other imaging examinations (CT, MR, etc.) suggest bladder masses and are suspicious for bladder cancer patients.
2. The bladder is well filled, and no allergic reactions to ultrasound contrast agents are found.
3. No surgery or radiotherapy/chemotherapy has been performed.
4. Patients who meet the indications for surgical resection and are planned for surgical treatment, including one of the following:

   1. Clinical symptoms consistent with suspected bladder cancer (such as gross hematuria, etc.);
   2. Patients with confirmed primary or recurrent bladder cancer by cystoscopic biopsy;
   3. Rapid urine cytology and urine cytology FISH testing suggest malignancy.

Exclusion Criteria:

1. Individuals unable to tolerate surgery;
2. Individuals allergic to ultrasound contrast agents, unable to undergo ultrasound contrast examination;
3. Unsuccessful preoperative ultrasound contrast examination or non-compliant patients;
4. Postoperative pathology does not indicate bladder cancer;
5. Patients who have undergone chemotherapy or radiation therapy.

Where it's running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Qiyun Ou, Dr. — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Study coordinator: Qiyun Ou, Dr.
• Email: ouqy5@mail.sysu.edu.cn
• Phone: (86)020-34071020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using ultrasound to improve diagnosis of bladder cancer staging

  This study is testing if using a special ultrasound technique can help doctors better determine the stage of bladder cancer in patients who haven't had treatment yet.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06775977

• Deep-learning ultrasound system for precise diagnosis of bladder tumors

  This project will try a deep-learning system that reads ultrasound images to automatically segment bladder tumors, estimate T-stage, and predict tumor grade for adults with suspected bladder masses.

  Recruiting Peking University First Hospital · Beijing · NCT07111364

• Impact of comorbidities after radical cystectomy using an AI-based predictive method

  This study tests whether an AI-based method can help predict outcomes for bladder cancer patients undergoing radical cystectomy, focusing on how comorbidities influence treatment choices and survival.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT05204186

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.